Results 91 to 100 of about 46,899 (191)

Regulation of sebaceous gland homeostasis and sebum secretion by the ERBB receptor family. [PDF]

iScience
Hommel T, Schneider MR, Dahlhoff M.
europepmc   +1 more source

ErbB family receptor dimerization dynamics and dysregulation via long-term single-molecule imaging. [PDF]

Cell
Ma K, Ma X, Shida JF, Niu Z, Lin YK, Mandal S, Dobbins A, Golomb L, Eck MJ, Greulich H, Meyerson M, Peng CS.   +11 more
europepmc   +1 more source

Genomic Landscape Analysis of Canine Pulmonary Adenocarcinoma Reveals Candidate Targetable Gene Fusions. [PDF]

Vet Comp Oncol
Sakthikumar S, Hendricks WPD, Rainford D, Selleck W, Briones N, Coggins C, Quan N, Zismann V, Lorch G, Sekulic A, Trent JM.   +10 more
europepmc   +1 more source

Transcriptomic Profiling Identifies Key Genes and ERBB Signaling Pathway Associated with Aggressive Behavior in Muscovy Ducks (<i>Cairina moschata</i>). [PDF]

Animals (Basel)
Liu A, Wang X, Zhou X, Yao B, Zhu J, Rao Y, Liao F, Yao B, Boonanuntan S, Yang S.   +9 more
europepmc   +1 more source

A descriptive multilevel analysis associating COVID-19 with polymyositis: from genetic markers and candidate mediators to clinical hematological profiles. [PDF]

Front Med (Lausanne)
Chen M, Li H, Tong X, Zhang X.
europepmc   +1 more source

X-ray crystal structure and in silico investigation of Tetrabromo thia-bridged diquinoline including anticancer mechanisms via target prediction and molecular docking. [PDF]

Sci Rep
Alshahateet SF, Al-Mazaideh GM, Al-Trawneh SA, Al-Taweel SA, Jodeh S.   +4 more
europepmc   +1 more source

HER2-Mutant Non-Small Cell Lung Cancer Podcast: Knowledge Is Power. [PDF]

Target Oncol
Subbiah V, Dietrich M, Le X.
europepmc   +1 more source

Poziotinib for uncommon ERBB mutations [PDF]

Nature Reviews Clinical Oncology, 2018
openaire   +2 more sources

Protocol for identifying properties of ERBB receptor antagonists using the barcoded ERBBprofiler assay. [PDF]

STAR Protoc
Popović L, Brankatschk B, Rossner MJ, Wehr MC.   +3 more
europepmc   +1 more source

Recurrent cancer-associated ERBB4 mutations are transforming and confer resistance to targeted therapies. [PDF]

Mol Oncol
Ojala VK, Ahonen S, Peltola S, Tuohisto-Kokko A, Esparta O, Suominen P, Jokilammi A, Farahani I, Chakroborty D, Dibus N, Boettcher S, Airenne TT, Johnson MS, Eli LD, Elenius K, Kurppa KJ.   +15 more
europepmc   +1 more source